Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding round
(Getty / E+ / Geber86) After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay. Nearly doubling that already impressive B round, the Cambridge, Massachusetts-based biotech has nabbed $226 million, with goals of unseating Pfizerโs Prevnar franchise as well as pushing a set of vaccines for hospital-associated infections into the clinic. ...
United States New Zealand General New Zealand United Kingdom Steve Brugger Bain Capital Life Sciences
Source: fiercebiotech.com